Elanco Animal Health Incorporated (NYSE:ELAN) Stock Has Average Price Target of $29.70 According to Brokerages

Elanco Animal Health Incorporated (NYSE:ELAN) has been given a consensus recommendation of “Moderate Buy” by the twelve research firms that are currently covering the stock, Marketbeat Ratings reports. One research analyst has rated the stock with a sell rating, two have given a hold rating, eight have given a buy rating and one has issued a strong buy rating on the company. The average 1-year target price among analysts that have issued ratings on the stock in the last year is $29.70.

Several equities research analysts have recently weighed in on ELAN shares. TD Cowen upped their target price on shares of Elanco Animal Health from $31.00 to $32.00 and gave the stock a “buy” rating in a report on Thursday, June 18th. Weiss Ratings raised shares of Elanco Animal Health from a “sell (d)” rating to a “sell (d+)” rating in a report on Friday, September 4th. UBS Group upped their price objective on shares of Elanco Animal Health from $31.00 to $33.00 and gave the stock a “buy” rating in a research note on Thursday, August 6th. Morgan Stanley raised their price objective on shares of Elanco Animal Health from $23.00 to $26.00 and gave the stock an “equal weight” rating in a report on Wednesday, July 22nd. Finally, Piper Sandler reiterated an “overweight” rating on shares of Elanco Animal Health in a research note on Monday, June 29th.

Insider Buying and Selling at Elanco Animal Health

In other Elanco Animal Health news, Director Lawrence Kurzius bought 40,000 shares of Elanco Animal Health stock in a transaction dated Thursday, August 20th. The shares were bought at an average price of $23.40 per share, with a total value of $936,000.00. Following the purchase, the director owned 188,647 shares of the company’s stock, valued at $4,414,339.80. This trade represents a 26.91% increase in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CFO Robert M. Vanhimbergen bought 4,200 shares of the stock in a transaction on Friday, August 7th. The shares were acquired at an average cost of $23.08 per share, with a total value of $96,936.00. Following the acquisition, the chief financial officer directly owned 137,516 shares in the company, valued at approximately $3,173,869.28. This trade represents a 3.15% increase in their position. The disclosure for this purchase is available in the SEC filing. Insiders purchased 63,198 shares of company stock valued at $1,473,109 over the last three months. Insiders own 1.14% of the company’s stock.

Institutional Trading of Elanco Animal Health

A number of large investors have recently made changes to their positions in ELAN. State Street Corp increased its position in shares of Elanco Animal Health by 4.7% during the second quarter. State Street Corp now owns 16,063,046 shares of the company’s stock worth $395,312,000 after acquiring an additional 726,567 shares in the last quarter. Anchor Investment Management LLC bought a new stake in shares of Elanco Animal Health in the second quarter valued at about $29,000. Talon Private Wealth LLC acquired a new position in shares of Elanco Animal Health during the second quarter worth about $780,000. The Manufacturers Life Insurance Company boosted its position in shares of Elanco Animal Health by 34.1% during the second quarter. The Manufacturers Life Insurance Company now owns 8,355,772 shares of the company’s stock worth $205,636,000 after buying an additional 2,126,727 shares during the period. Finally, Tidal Investments LLC grew its holdings in shares of Elanco Animal Health by 1.4% during the second quarter. Tidal Investments LLC now owns 317,878 shares of the company’s stock worth $7,823,000 after buying an additional 4,349 shares in the last quarter. Institutional investors own 97.48% of the company’s stock.

Elanco Animal Health Stock Performance

NYSE ELAN opened at $21.78 on Friday. The stock has a market cap of $10.88 billion, a P/E ratio of -53.13, a PEG ratio of 1.60 and a beta of 1.71. The company’s 50-day simple moving average is $23.81 and its 200 day simple moving average is $23.72. Elanco Animal Health has a twelve month low of $19.40 and a twelve month high of $27.98. The company has a quick ratio of 1.10, a current ratio of 2.05 and a debt-to-equity ratio of 0.58.

Elanco Animal Health (NYSE:ELAN) last announced its quarterly earnings results on Wednesday, August 5th. The company reported $0.34 EPS for the quarter, topping analysts’ consensus estimates of $0.27 by $0.07. The firm had revenue of $1.37 billion during the quarter, compared to analysts’ expectations of $1.31 billion. Elanco Animal Health had a negative net margin of 3.96% and a positive return on equity of 8.13%. The company’s revenue for the quarter was up 10.2% compared to the same quarter last year. During the same quarter last year, the company earned $0.26 earnings per share. Elanco Animal Health has set its Q3 2026 guidance at 0.190-0.220 EPS and its FY 2026 guidance at 1.100-1.160 EPS. As a group, research analysts forecast that Elanco Animal Health will post 1.13 earnings per share for the current fiscal year.

Elanco Animal Health Company Profile

Elanco Animal Health Incorporated is a global animal health company that develops, manufactures and markets products for pets and food-producing animals. Its portfolio includes veterinary pharmaceuticals, vaccines, parasiticides, nutritional products and other solutions designed to prevent and treat disease, improve animal well-being and support livestock productivity.

For companion animals, Elanco offers products addressing pain, osteoarthritis, dermatological conditions, infectious diseases and flea, tick and intestinal parasite control.